Ropeginterferon Alfa-2b (Besremi)

Canada’s Drug Agency (CDA-AMC) recommends that Besremi be reimbursed by public drug plans for the treatment of adult patients with polycythemia vera (PV) requiring cytoreductive therapy if certain conditions are met. The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) determined that it is uncertain whether Besremi demonstrates acceptable clinical value versus hydroxyurea, peginterferon alfa-2a, and ruxolitinib in patients with PV requiring cytoreductive therapy. Given that Besremi is expected to be an alternative treatment to hydroxyurea, acceptable clinical value refers to at least comparable value versus hydroxyurea. Evidence from a clinical trial failed to show that Besremi is noninferior to hydroxyurea at 12 months in patients with PV requiring cytoreductive therapy. However, the evidence from the completed long-term extension study suggested numerical improvements in disease response rates, complete hematological response, molecular response, and change in JAK2 allele burden when Besremi was compared to best available therapy. Evidence from an indirect treatment comparison showed that the complete hematological response was similar between Besremi and peginterferon alfa-2a in patients with PV. pERC has established that there is significant unmet clinical need for additional cytoreductive treatment options for PV. Currently, there are limited treatment options with hydroxyurea used off-label as the main first-line option. There are challenges with hydroxyurea as patients may develop intolerance or resistance; hydroxyurea may be unsuitable for those ofd reproductive age; and there have been recent supply shortages, rendering the need for more treatment options for patients. pERC concluded that Besremi addresses a significant unmet need to a degree that justifies a positive recommendation despite the uncertainty in clinical value.

Authors

Publication Details

Journal
Canadian Journal of Health Technologies
Published
2026-11-17
DOI
https://doi.org/10.51731/cjht.2026.1570
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ropeginterferon Alfa-2b (Besremi)

CDA-AMC
Canadian Journal of Health Technologies
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Ropeginterferon Alfa-2b (Besremi)

CDA-AMC
article en

Abstract

Canada’s Drug Agency (CDA-AMC) recommends that Besremi be reimbursed by public drug plans for the treatment of adult patients with polycythemia vera (PV) requiring cytoreductive therapy if certain conditions are met. The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) determined that it is uncertain whether Besremi demonstrates acceptable clinical value versus hydroxyurea, peginterferon alfa-2a, and ruxolitinib in patients with PV requiring cytoreductive therapy. Given that Besremi is expected to be an alternative treatment to hydroxyurea, acceptable clinical value refers to at least comparable value versus hydroxyurea. Evidence from a clinical trial failed to show that Besremi is noninferior to hydroxyurea at 12 months in patients with PV requiring cytoreductive therapy. However, the evidence from the completed long-term extension study suggested numerical improvements in disease response rates, complete hematological response, molecular response, and change in JAK2 allele burden when Besremi was compared to best available therapy. Evidence from an indirect treatment comparison showed that the complete hematological response was similar between Besremi and peginterferon alfa-2a in patients with PV. pERC has established that there is significant unmet clinical need for additional cytoreductive treatment options for PV. Currently, there are limited treatment options with hydroxyurea used off-label as the main first-line option. There are challenges with hydroxyurea as patients may develop intolerance or resistance; hydroxyurea may be unsuitable for those ofd reproductive age; and there have been recent supply shortages, rendering the need for more treatment options for patients. pERC concluded that Besremi addresses a significant unmet need to a degree that justifies a positive recommendation despite the uncertainty in clinical value.

Canadian Journal of Health TechnologiesVol. 6(11)
Good health and well-being
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon